Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [2]

Journal of Hepatology

Volumn 30, Issue 1, 1999, Pages 174-

  Kaffy, F ^a   Borderie, C ^a   Chagneau, C ^a   Ripault, M P ^a   Larzilliere, I ^a   Silvain, C ^a   Beauchant, M ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

CREATININE CLEARANCE; DRUG SAFETY; HEPATORENAL SYNDROME; HUMAN; LETTER; PLASMA VOLUME; PRIORITY JOURNAL; SURVIVAL;

EID: 0032946277     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80025-7     Document Type: Letter

References (5)

1. MC Kew RR Varma DJ Sampson S Sherlock The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver Gut 33 1972 14 20
2. K Lenz H Hörtnagl W Druml H Reither R Schmid B Schneeweiss Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis Gastroenterology 101 1991 1060 1067
3. N Ganne-Carrié A Hadengue P Mathurin F Durand S Erlinger JP Benhamou Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation Dig Dis Sci 41 1996 1054 1056
4. V Arroyo P Gines AL Gerges FJ Dudley P Gentilini G Laffi Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 1996 164 176
5. M Guevara P Gines G Fernandez-Esparrach P Sort JM Salmeron W Jimenez Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1998 35 41